OvaScience (OVAS) PT Trimmed at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
OvaScience Reports First Quarter 2015 Financial Results
May 11, 2015 4:05 PM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported first quarter 2015 financial results and highlighted recent accomplishments.
We are confident in our ability to achieve our goals this year as demand for the AUGMENT treatment grows and we make progress toward bringing other new options to patients, said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. This quarter, we were pleased that physicians providing our AUGMENT treatment reported clinical pregnancies in women with very poor... More
